<DOC>
	<DOCNO>NCT00096954</DOCNO>
	<brief_summary>This multicenter , parallel-group , double-blind , randomize , placebo-controlled study enrol 333 subject . These subject 12-75 year old atopic asthma , elevate serum total Immunoglobulin E ( IgE ) , baseline force expiratory volume 1 second ( FEV1 ) ≥ 80 % predict , inhaled corticosteroid without controller asthma medication ( e.g. , long-acting β2-agonists [ LABAs ] , leukotriene receptor antagonist [ LTRA ] , immunotherapy ) .</brief_summary>
	<brief_title>A Prospective , Randomized , Double-Blind Study Efficacy Omalizumab ( Xolair ) Atopic Asthmatics With Good Lung Capacity Who Remain Difficult Treat ( EXACT )</brief_title>
	<detailed_description />
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Have document history asthma well evidence ≥ 12 % reversibility FEV1 . Evidence ≥ 12 % reversibility FEV1 may obtain one follow measure : 1 ) Documentation ≥ 12 % reversibility FEV1 albuterol administration time precede 24 month ; 2 ) Documentation ≥ 12 % improvement FEV1 two separate measurement obtain within 4week period surround asthma exacerbation precede 24 month ; 3 ) Demonstration ≥ 12 % reversibility FEV1 albuterol administration time screen Have baseline FEV1 ≥ 80 % predict normal value prior randomization Have positive skin test ( diameter wheal ≥ 3 mm vs. control ) vitro radioallergosorbent test ( RAST ( R ) ) ImmunoCap ( R ) one relevant perennial aeroallergen cat house dust mite document within previous year Be receive least inhaled corticosteroid dosage fluticasone dry powder inhaler ( DPI ) ≥ 200 ug/day equivalent exvalve dose 12 week prior screen visit During 4week runin period prior randomization , demonstrate evidence inadequate asthma symptom control despite inhaled corticosteroid without controller asthma medication ( e.g. , LABA , LTRA , immunotherapy ) . Inadequate asthma symptom control define least one follow report subject diary card 4week runin period : Daytime asthma symptom score ≥ 1 ( scale 04 ) least 20 28 day ( miss data treat day symptom ) mean symptom score ≥ 1.5 ( mean calculate base data supply ; miss value consider ) Nighttime awaken asthma symptom ( 4 time 4week runin period ) Meet study drugdosing table eligibility criterion ( serum baseline IgE level ≥ 30 ≤ 1300 IU/mL body weight ≥ 20 ≤ 150 kg ) If female childbearing potential , use effective method contraception ( opinion investigator ) prevent pregnancy agree continue practice acceptable method contraception duration participation study Have receive chronic systemic corticosteroid ( oral intravenous ) within 3 month receive burst oral corticosteroid within last 2 week prior screen Have receive Xolair therapy time within 12 month prior screen Are pregnant lactate Have know hypersensitivity ingredient Xolair , include excipients ( sucrose , histidine , polysorbate 20 ) Have lifetime history smoking &gt; 10pack year Have active lung disease asthma ( e.g. , chronic bronchitis , emphysema , cystic fibrosis , chronic obstructive pulmonary disease ) Have history upper respiratory infection lower respiratory infection within 30 day prior randomization Have diagnosis aspirin nonsteroidal antiinflammatory druginduced asthma Have take immunosuppressant investigational drug within 30 day prior screen Have significant medical illness asthma</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Omalizumab ( Xolair )</keyword>
	<keyword>Atopic Asthma</keyword>
</DOC>